Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 114 clinical trials
Study of Acalabrutinib and Tafasitamab in MZL Patients

This is a multicenter open label phase II trial in patients with previously treated Marginal Zone Lymphomas. The aim of the study is to evaluate the efficacy and the safety of tafasitamab in combination with acalabrutinib. Twenty-four patients are expected to be enrolled and treated every 28 days with acalabrutinib …

  • 0 views
  • 24 May, 2022
  • 4 locations
IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3K Inhibitor, in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

  • 0 views
  • 24 Jan, 2021
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma

A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma

marginal zone lymphoma
follicular lymphoma
measurable disease
  • 0 views
  • 17 Jun, 2021
  • 36 locations
A Novel Vaccine (EO2463) as Monotherapy and in Combination for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL

indolent non-hodgkin lymphoma
rituximab
tumor burden
lenalidomide
measurable disease
  • 0 views
  • 01 Aug, 2021
  • 5 locations
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

This trial studies the effectivity of low-dose radiation therapy with 10x2Gy for the treatment of patients with stage I-II stomach or duodenal Lymphoma (Marginal Zone or Follicular)

marginal zone lymphoma
follicular lymphoma
  • 0 views
  • 11 Dec, 2021
  • 1 location
Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

This is an open-label, Phase II interventional study in order to assess efficacy and safety of single agent ublituximab as initial therapy for FL (Follicular lymphoma) and MZL (Marginal zone

  • 4 views
  • 28 Feb, 2021
  • 1 location
TLR8 Agonist VTX-2337 in Combo With Local Radiation in Low-Grade B-cell Lymphomas

The primary objective is to determine the local and systemic anti-tumor effects of intratumoral injection of VTX-2337, a TLR8 agonist, in combination with low-dose local radiation at a single tumor site, in patients with recurrent b-cell lymphoma.

lymphoma
b-cell lymphoma
  • 147 views
  • 08 Nov, 2020
  • 1 location
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.

cancer
lymphoma
marginal zone lymphoma
measurable disease
experimental drug
  • 9 views
  • 04 Mar, 2022
A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Marginal Zone Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus rituximab versus lenalidomide plus rituximab in participants with relapsed/refractory marginal zone lymphoma (R/R MZL

  • 0 views
  • 23 Apr, 2022
  • 1 location
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells called Autologous T Lymphocyte Chimeric Antigen Receptor (ATLCAR) cells targeted against the kappa light chain antibody on cancer cells. For this study, the anti-kappa …

cancer
bendamustine
leukemia
marginal zone lymphoma
monoclonal antibodies
  • 15 views
  • 09 Dec, 2021
  • 1 location